FDA Expands Teplizumab Approval for Pediatric Type 1 Diabetes

The U.S. Food and Drug Administration expanded its approval for teplizumab on November 11, 2026. This immunotherapy slows the immune system's destruction of the body's remaining insulin-producing cells. The expanded approval allows children and adolescents ages 8 to 17 who are newly diagnosed with stage 3 type 1 diabetes to access the treatment. This new indication was granted under the FDA's accelerated approval pathway.

The approval provides a new treatment option for type 1 diabetes by targeting the underlying autoimmune disease, rather than solely managing blood sugar levels with insulin. This regulatory action affects the market for immunotherapies and diabetes care in the United States of America.